 announced today that Pearl Therapeuticshas selected SimpleCTMS as their 

to optimize the management of their global clinical studies.

The initial Pearl deployment includes multiple Phase II global studies in which SimpleCTMS will be deployed for study startup planning and ongoing study tracking. SimpleCTMS will improve data transparency across service providers, and integrate with other key eClinical systems utilized by Pearl.

The selection of SimpleCTMS by Pearl Therapeutics comes after the successful completion of a CTMS Pilot Program, during which the SimpleCTMS product management and customer support teams were able to quickly and effectively meet and exceed the customer's needs.

SimpleCTMS was designed and developed to offer the benefits of a CTMS (Clinical Trial Management System) without the extensive upfront financial and resource commitments associated with traditional enterprise systems or the inherent inefficiencies of worksheet trackers. Offering flexible subscription pricing, SimpleCTMS provides early stage drug developers a scalable and cost effective solution to improve the management, performance and study startup costs associated with clinical trials.